Seres Therapeutics Inc
F:1S9

Watchlist Manager
Seres Therapeutics Inc Logo
Seres Therapeutics Inc
F:1S9
Watchlist
Price: 0.2 EUR
Market Cap: 30.3m EUR

Operating Margin

-29 467%
Current
Declining
by 22 597.9%
vs 3-y average of -6 869%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-29 467%
=
Operating Income
$-103.4m
/
Revenue
$351k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-29 467%
=
Operating Income
€-103.4m
/
Revenue
$351k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Seres Therapeutics Inc
NASDAQ:MCRB
139.9m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
40.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 98% of companies in the United States of America
Percentile
2st
Based on 14 112 companies
2st percentile
-29 467%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Seres Therapeutics Inc
Glance View

Market Cap
30.3m EUR
Industry
Biotechnology

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).

1S9 Intrinsic Value
0.003 EUR
Overvaluation 98%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-29 467%
=
Operating Income
$-103.4m
/
Revenue
$351k
What is Seres Therapeutics Inc's current Operating Margin?

The current Operating Margin for Seres Therapeutics Inc is -29 467%, which is below its 3-year median of -6 869%.

How has Operating Margin changed over time?

Over the last 3 years, Seres Therapeutics Inc’s Operating Margin has decreased from -1 701.9% to -29 467%. During this period, it reached a low of -29 467% on Oct 30, 2025 and a high of -54.1% on Mar 31, 2024.

Back to Top